Table 2

Skp2 expression in 622 human prostate cancersa

nbSkp2 labeling frequency (%)
MedianMean ± SE
Patients62230.036.321.22
Preoperative PSA (ng/ml)
 <49415.028.792.98
 4–1032530.037.961.70
 10–2011230.035.002.83
 >207245.044.443.54
Clinical stage (UICCc system)
 T121630.034.562.03
 T235930.035.621.63
 T34360.048.724.36
Gleason score
 3–627720.031.961.79
 730435.039.261.76
 8–104150.043.934.77
ECE
 Yes26330.038.221.88
 No35930.034.921.61
Margins positive
 Yes8830.035.073.27
 No53430.036.521.32
Seminal vesicle involvement
 Yes8330.038.573.03
 No53930.035.971.33
Lymph node involvement
 Yes4255.044.524.54
 No58030.035.721.27
  • a Skp2 levels expressed as nuclear labeling frequency of cancer cells in tissue microarray composed of 622 radical prostatectomy specimens stratified according to their pathological and clinical features.

  • b Number of specimens.

  • c UICC, Union International Centre Cancer.